About Event
What You Missed from the 2nd ADC Pharmacokinetics & Clinical Pharmacology Summit?
The FDA’s Project Optimus is changing the game, and ADC clinical pharmacology guidelines are evolving fast. Getting the dose right, balancing safety and efficacy, has never been more crucial.
Modern ADCs aren’t simple - they’re novel conjugates, dual payloads, and combination therapies that push the boundaries of traditional dosing. At the 2nd ADC Pharmacokinetics & Clinical Pharmacology Summit, 40+ experts in PKPD, pharmacometrics, modeling, and bioanalysis came together to share insights, tackle real-world challenges, and help you define optimal dosing strategies from day one.
You missed the chance to collaborate, learn, and accelerate the path to safer, more effective ADCs for patients.
2025 Event Highlights:
Examine approaches to dosing novel conjugates
Investigate non-traditional payloads and bispecific ADCs to understand how unique PK properties influence clinical outcomes, with insights from AstraZeneca
Learn from real-world case studies
Explore dose optimization and adjustment through modeling and simulation, presented by Astellas Pharma
Investigate tumor internalization mechanisms
Join AbbVie & Daichii Sankyo using bioanalytical methods to assess structural integrity and DAR for deeper insights into drug clearance
Advance clinical dosing strategies
Apply QSP platforms with Novartis to rigorously evaluate the predictive value of computational modeling
Close the translational gap in PK/PD
Leverage AI and enhance ADME parameter understanding with Sutro Biopharma
Download the Full Event Guide to Discover:
- Hands-on workshops exploring the latest in novel conjugates and combination therapies
- Insider talks from AstraZeneca, Daiichi Sankyo, Genentech, and other industry leaders
- Interactive roundtables where your voice drives the discussion
- Premium networking opportunities to connect with the people shaping ADC innovation
2025 Attending Companies Included:
